Blog: Research

Low-dose Naltrexone Changes Levels of Inflammatory Proteins in MS, Study Shows

21 February 2018

Source Multiple Sclerosis News Today:

Inhibition of the neuroactive opioid growth factor (OGF) alters the blood levels of important pro- and anti-inflammatory proteins in mice with multiple sclerosis (MS)-like disease.

A £10 gesture of thanks offered to MS participants who complete survey

9 February 2018

Opinion Health is currently conducting a study that involves patients with multiple sclerosis, and we would like to kindly ask for your support.

NICE proposes rejecting five drugs for relapsing MS - MS Trust responds

31 January 2018

Source MS Trust:

NICE has recommended Extavia, but rejected Copaxone, Avonex, Betaferon, Plegridy and Rebif in its preliminary appraisal of MS drugs. The MS Trust has responded to NICE’s consultation in the strongest possible terms.

Men hold secret to protect women from multiple sclerosis

31 January 2018

Source EurekAlert:

Guardian molecule induced by testosterone reverses harmful immune response, eliminates disease symptoms in female mice.

Ocrelizumab licensed for people with early primary progressive MS in the UK

22 January 2018

Source MS Society:

Ocrelizumab has been approved as the first licensed treatment for some people with primary progressive MS in the UK.

The MS Society explore 5 myths about cannabis and MS

23 November 2017

Source MS Society:

There’s mounting evidence to show that cannabis could help pain and muscle spasms for people with MS. But with tonnes of information swirling around the internet, it’s hard to be sure what’s true and what’s not.

We dived into the details to bust 5 common myths about cannabis and MS:

1. ‘Cannabis for medicinal use’ means any kind of cannabis

This can be confusing, as the media often refers to both licensed cannabis products and the illegal...

Ozanimod Superior to Avonex in Treating Relapsing MS in Phase 3 Trials, Celgene Reports

23 November 2017

Source Multiple Sclerosis News Today:

Celgene released the results of two Phase 3 trials showing that patients with relapsing multiple sclerosis (MS) who were treated with ozanimod had lower relapse rates and fewer MRI brain lesions compared to those given a current first-line therapy, Avonex (interferon β-1a).

These results will be used to support a request for ozanimod’s approval as an MS therapy with the U.S. Food and Drug Administration (FDA), a filing known as a New Drug...

Cannabinoid, Dronabinol, Seen as Long-term Treatment Option for Neuropathic Pain in Phase 3 Study

23 November 2017

Source Multiple Sclerosis News Today:

Multiple sclerosis (MS) patients being treated with dronabinol, a cannabinoid, do not show signs of drug abuse or dependency, leading researchers to conclude it has potential to be a long-term and safe treatment option for neuropathic pain.

The Search for a Miracle Cure - Channel 4, 23rd November at 10pm

23 November 2017

Source Radio Times:

Documentary following leading lawyer Mark Lewis, the man who fought the News of the World in the phone hacking scandal, as he joins a clinical trial that might offer a breakthrough cure for multiple sclerosis. He learned he had the condition at the age of 25 but his high-profile battle with the tabloids has exacerbated his symptoms. Now 50, he travels to Hadassah University Medical Centre in Jerusalem, where the work being done could have a positive impact on...

Targeting Blood-clotting Protein Can Restore Brain’s Potential to Repair Myelin Layer, Study Shows

8 November 2017

Source Multiple Sclerosis News Today:

A blood-clotting protein called fibrinogen prevents myelin production and blocks the neuron remyelination repair process in mice, a study finds.